Goldentree Asset Management LP Takes $149.60 Million Position in Jazz Pharmaceuticals PLC $JAZZ

Goldentree Asset Management LP purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,137,106 shares of the specialty pharmaceutical company’s stock, valued at approximately $149,597,000. Jazz Pharmaceuticals makes up 12.4% of Goldentree Asset Management LP’s holdings, making the stock its 2nd biggest holding. Goldentree Asset Management LP owned about 1.87% of Jazz Pharmaceuticals as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Vestal Point Capital LP acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $127,344,000. Schonfeld Strategic Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 592.1% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock worth $57,523,000 after purchasing an additional 373,383 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Jazz Pharmaceuticals by 62.1% during the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after purchasing an additional 304,463 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Jazz Pharmaceuticals by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after purchasing an additional 298,815 shares during the last quarter. Finally, Woodline Partners LP lifted its stake in shares of Jazz Pharmaceuticals by 710.7% in the 3rd quarter. Woodline Partners LP now owns 264,968 shares of the specialty pharmaceutical company’s stock valued at $34,923,000 after purchasing an additional 232,284 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.5%

Jazz Pharmaceuticals stock opened at $180.45 on Thursday. The firm has a market cap of $11.11 billion, a price-to-earnings ratio of -30.23, a P/E/G ratio of 0.33 and a beta of 0.22. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $198.00. The firm has a fifty day moving average price of $172.99 and a two-hundred day moving average price of $157.36.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.49 by $0.15. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The firm’s revenue was up 8.1% compared to the same quarter last year. During the same period last year, the business posted $6.51 earnings per share. As a group, analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 55,600 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $191.56, for a total value of $10,650,736.00. Following the sale, the executive vice president owned 56,862 shares of the company’s stock, valued at $10,892,484.72. This trade represents a 49.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $194.49, for a total value of $1,039,160.07. Following the completion of the transaction, the senior vice president directly owned 28,728 shares in the company, valued at approximately $5,587,308.72. This represents a 15.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 68,015 shares of company stock worth $13,037,486. Corporate insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

JAZZ has been the topic of several analyst reports. Piper Sandler reissued an “overweight” rating and set a $219.00 target price (up from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. Wells Fargo & Company upped their price target on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Truist Financial increased their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Monday, January 12th. TD Cowen reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $214.38.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.